Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (symbol: PSTV) is a cutting-edge clinical-stage pharmaceutical company based in Austin, Texas. Founded in 1996 and initially known as Cytori Therapeutics, Inc., the company rebranded to Plus Therapeutics in July 2019 to better reflect its mission and evolving focus. Specializing in the discovery, development, and manufacture of innovative treatments for cancer and other debilitating diseases, Plus Therapeutics aims to bring new hope to patients through cutting-edge medical solutions.
The company's lead product candidate is DocePLUS, a protein-stabilized, pegylated liposomal formulation of docetaxel specifically designed for the treatment of small cell lung cancer. Additionally, Plus Therapeutics is developing DoxoPLUS, a generic pegylated liposomal encapsulated doxorubicin aimed at treating breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma.
In a significant partnership, Plus Therapeutics has entered into a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. This collaboration aims to propel the company further into the forefront of cancer treatment research.
One of the company's groundbreaking developments is the novel injectable radiotherapy called Rhenium (186Re) obisbemeda. This treatment is specifically formulated to deliver targeted high-dose radiation in Central Nervous System (CNS) tumors, optimizing patient outcomes while minimizing off-target risks. The product's efficacy and safety are being evaluated for recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. These trials are supported by grants from the National Cancer Institute (NCI) and the Cancer Prevention & Research Institute of Texas (CPRIT), totaling millions in funding.
Financially, Plus Therapeutics recently secured $6.5 million in upfront gross proceeds, with the potential to receive up to an additional $11.5 million through potential warrant exercise, amounting to approximately $18 million in total gross proceeds. These funds will be essential in advancing the company’s robust pipeline and bringing innovative treatments to market.
Investors and stakeholders can stay informed of the latest developments and financial updates by reaching out to key contacts such as Corey Davis, Ph.D. of LifeSci Advisors, and Charles Y. Huang, MBA, Director of Capital Markets and Investor Relations.
Plus Therapeutics (PSTV) announced it will report its second quarter 2021 financial results on July 22, 2021, after market close. A conference call and webcast to discuss the results and provide a corporate update will follow at 5:00 p.m. ET. Plus Therapeutics focuses on developing targeted radiotherapeutics for rare cancers, utilizing a nanotechnology platform for drug delivery and formulation. This innovative approach aims to enhance the safety and efficacy of treatments for difficult-to-treat cancers.
Plus Therapeutics (PSTV) announced a significant step forward in their ReSPECT™ trial for Rhenium NanoLiposome (RNL™) in treating recurrent glioblastoma (GBM). The Data and Safety Monitoring Board has approved advancing to the eighth cohort, which will feature a 40% increase in total radioactivity, escalating the infused dose to 31.2 millicuries. RNL™ has demonstrated a favorable safety profile with no dose-limiting toxicities observed in the first seven cohorts, treating 21 patients. The trial is supported by the NIH/National Cancer Institute at three U.S. sites.
Plus Therapeutics (PSTV) announced a poster presentation at the 6th Biennial Pediatric Neuro-Oncology Research Conference. The poster focuses on a Phase I study of Rhenium-186 Nanoliposomes (186RNL) for treating ependymoma and high-grade glioma. Dr. Ashley S. Plant-Fox from Northwestern University leads the presentation. The FDA has provided positive feedback on their study synopsis and confirmed no additional toxicology studies are needed for pediatric trials. RNL has also received Orphan Drug and Fast Track designations for glioblastoma treatment.
AUSTIN, Texas, June 9, 2021 – Plus Therapeutics (Nasdaq: PSTV) has announced that President and CEO Marc H. Hedrick M.D. will participate in the BIO Digital Conference on June 10-11 and 14-18, 2021. The conference presentation will be accessible on-demand on the conference website. Following the event, it will also be available in the Investors section of Plus Therapeutics' website. The company focuses on nanoliposome-encapsulated radionuclides for cancer treatment, enhancing drug delivery and efficacy for rare cancers.
Plus Therapeutics (PSTV) announced two collaboration agreements aimed at advancing the cGMP manufacturing processes for Rhenium NanoLiposome (RNL™), targeting recurrent glioblastoma. The partnerships include Invicro LLC for process development and imaging support, and Eurofins BioPharma for developing test methods for purity and compliance. These agreements are crucial for progressing RNL™ to registrational clinical trials and eventual commercial supply, according to CEO Marc H. Hedrick. Previous agreements include a master services engagement with Piramal Pharma Solutions for RNL™ production.
Plus Therapeutics, Inc. (Nasdaq: PSTV) reported first-quarter financial results for 2021, highlighting a cash balance of $14.4 million, up from $8.3 million at year-end 2020. The company posted a net loss of $2.7 million, or $(0.33) per share, compared to a net loss of $1.1 million, or $(0.28) per share, in Q1 2020. Key developments include advancements in their lead drug Rhenium NanoLiposome (RNL™) for treating rare cancers, and progress in clinical trials, including treatment for recurrent glioblastoma and upcoming FDA meetings. A conference call is scheduled for April 22, 2021, at 5:00 p.m. ET.
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on therapies for rare cancers, will report its first quarter 2021 financial results on April 22, 2021, after market close. Following the earnings announcement, a conference call and webcast will take place at 5:00 PM ET to discuss results and provide a corporate update. Plus Therapeutics utilizes a unique nanotechnology platform aimed at enhancing drug delivery and efficacy for difficult-to-treat cancers. Details for the conference call and webcast are available on their website.
Plus Therapeutics (Nasdaq: PSTV) has signed a master services agreement (MSA) with Piramal Pharma Solutions for the development of its Rhenium NanoLiposome (RNL™), aimed at treating rare cancers, including glioblastoma. The agreement entails transferring analytical and microbiological methods, production processes, and stability studies, executed at Piramal's facility in Lexington, Kentucky. This partnership is expected to pave the way for future clinical and commercial supply agreements. The collaboration marks a significant milestone in advancing RNL towards regulatory approval.
Plus Therapeutics (Nasdaq: PSTV) announced that CEO Marc Hedrick will present at two upcoming virtual conferences. The first event is the BIO-Europe Spring Digital 2021 from March 22-25, with presentations available on demand starting March 22. The second event is the Q1 Virtual Investor Summit, taking place March 23-25, with a scheduled presentation on March 23 at 11:30 a.m. ET. Investors interested in meetings should contact conference coordinators. Webcasts will be available on Plus Therapeutics' website under 'Events' in the Investor Relations section.
Plus Therapeutics (Nasdaq: PSTV) has announced that Marc Hedrick, M.D., the Company’s President and CEO, will present at two upcoming virtual conferences. The first is the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021, with the presentation available on demand starting March 9. The second is the Maxim Emerging Growth Conference on March 17-18, 2021, with on-demand access beginning March 17. Investors interested in meetings can contact conference coordinators. For more details, visit PlusTherapeutics.com.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
What is Plus Therapeutics, Inc.?
What are the main products of Plus Therapeutics?
What is Rhenium (186Re) obisbemeda?
What partnerships does Plus Therapeutics have?
What recent financial achievements has Plus Therapeutics made?
Where is Plus Therapeutics headquartered?
What clinical trials is Plus Therapeutics involved in?
Who can investors contact for more information?
What was the former name of Plus Therapeutics?
When was Plus Therapeutics founded?
